Evidence map›Paper›PMID 36140339›Full record

ArticleBiomedicines2022

A Protein Microarray-Based Respiratory Viral Antigen Testing Platform for COVID-19 Surveillance.

Sungjun Beck, Rie Nakajima, Algis Jasinskas, Timothy J Abram, Sun Jin Kim, Nader Bigdeli, Delia F Tifrea, Jenny Hernandez-Davies, D Huw Davies, Per Niklas Hedde and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sungjun BeckDepartment of Biological Chemistry, University of California, Irvine, CA 92697, USA.
Rie NakajimaDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Algis JasinskasDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Timothy J AbramVelox Biosystems, 5 Mason, Suite 160, Irvine, CA 92618, USA.
Sun Jin KimDepartment of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.
Nader BigdeliStudent Health Center, University of California, Irvine, CA 92697, USA.
Delia F TifreaDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.
Jenny Hernandez-DaviesDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
D Huw DaviesDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Per Niklas HeddeDepartment of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.ORCID 0000-0002-2994-369X
Philip L FelgnerDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Weian ZhaoDepartment of Biological Chemistry, University of California, Irvine, CA 92697, USA.
University of California, Irvine · USFluor (United States) · US

Funding

UC BRAID Center for Accelerated Innovation COVID-19 diagnostic project developmentU54HL119893 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PALAZZOLO, MICHAEL J · 2013 to 2020
$18.3M
NHLBI NIH HHS U54 HL119893NHLBI NIH HHS U54HL119893NIBIB NIH HHS supplemental fundingUC Irvine CRAFT-COVID
6 · The paper itself

Abstract

High-throughput and rapid screening testing is highly desirable to effectively combat the rapidly evolving COVID-19 pandemic co-presents with influenza and seasonal common cold epidemics. Here, we present a general workflow for iterative development and validation of an antibody-based microarray assay for the detection of a respiratory viral panel: (a) antibody screening to quickly identify optimal reagents and assay conditions, (b) immunofluorescence assay design including signal amplification for low viral titers, (c) assay characterization with recombinant proteins, inactivated viral samples and clinical samples, and (d) multiplexing to detect a panel of common respiratory viruses. Using RT-PCR-confirmed SARS-CoV-2 positive and negative pharyngeal swab samples, we demonstrated that the antibody microarray assay exhibited a clinical sensitivity and specificity of 77.2% and 100%, respectively, which are comparable to existing FDA-authorized antigen tests. Moreover, the microarray assay is correlated with RT-PCR cycle threshold (Ct) values and is particularly effective in identifying high viral titers. The multiplexed assay can selectively detect SARS-CoV-2 and influenza virus, which can be used to discriminate these viral infections that share similar symptoms. Such protein microarray technology is amenable for scale-up and automation and can be broadly applied as a both diagnostic and research tool.

Indexed as

antibody microarrayantigen testimmunofluorescence assayportable imagerprotein biotinylationSARS-CoV-2tyramide signal amplification

Identifiers

PMID36140339
PMCPMC9496200
OpenAlexW4295561084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.